ASND
NASDAQ HealthcareAscendis Pharma A/S - Ordinary Share
Biotechnology
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
๐ Market Data
| Price | $259.80 |
|---|---|
| Volume | 455,297 |
| Market Cap | 17.04B |
| RSI (14-Day) | 48.4 |
| 200-Day MA | $223.63 |
| 50-Day MA | $241.54 |
| 52-Week High | $282.15 |
| 52-Week Low | $160.86 |
| P/E Ratio | 30.14 |
| Forward P/E | 24.89 |
| Price / Book | 29.06 |
๐ฏ Investment Strategy Scores
ASND scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Institutional Whale (80/100) โ this strategy Large-cap, institutional-quality stocks.
Lowest fit among scored strategies: ๐ Moon Shot (12/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find ASND in your text
Paste any article, transcript, or post โ the tool will extract ASND and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.